Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis by Lazzarino, G et al.
 
1 
SERUM LACTATE AS A NOVEL POTENTIAL BIOMARKER IN 
MULTIPLE SCLEROSIS 
 
Angela M. Amorini,a Viviana Nociti,b Axel Petzold,c Claudio Gasperini,d Esmeralda Quartuccio,d 
Giacomo Lazzarino,a Valentina Di Pietro,e Antonio Belli,e Stefano Signoretti,d Roberto Vagnozzi,f  
Giuseppe Lazzarino,g* Barbara Tavazzia 
 
aInstitute of Biochemistry and Clinical Biochemistry, Catholic University of Rome, Italy 
bDon C. Gnocchi Foundation, Rome, Italy 
cDepartment of Neurology, VU Medical Centre, Amsterdam, The Netherlands 
dDepartment of Neurosciences, S Camillo Forlanini Hospital, Rome, Italy 
eNeuropharmacology and Neurobiology Section, School of Clinical and Experimental Medicine, 
College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 
fDepartment of Biomedicine and Prevention, Section of Neurosurgery, University of Rome “Tor 
Vergata”, Rome, Italy.  
gDepartment of Biology, Geology and Environmental Sciences, Division of Biochemistry and 
Molecular Biology, University of Catania, Catania, Italy. 
 
*Correspondence should be addressed to: Prof. Giuseppe Lazzarino 
Department of Biology, Geology and Environmental Sciences 
Division of Biochemistry and Molecular Biology 
University of Catania, Viale A. Doria 6, 95125 Catania, Italy 
Tel.: +39-0957384095; Fax: +39-095337036; E-mail: lazzarig@unict.it 
 
Running title: Serum lactate in MS 
 
Text word count = 4,019 
 
2 
ABSTRACT 
 
Multiple sclerosis (MS) is a primary inflammatory progressive demyelinating disorderdisease 
associated with a probably secondary progressive neuronegenerative component. , probably caused 
by an autoimmune attack towards myelin.  MS is characterized by mImpaired mitochondrial 
malfunctioning has been hypothesised to drive neurodegeneration and called, the “virtual hypoxia 
hypothesis” imbalancing adenosine triphosphate production and consumption and leading to cell 
energy deficit. Biochemical data of support to this hypothesis comes from Previous data showed 
that MS patients have increased lactate levels in both the brain tissue and cerebrospinal fluid studies 
with elevated lactate levels which suggest an increased anaerobic metabolism in MS. The aAim of 
thisour multicentre study was to determinetest whetherif this data could be extended to blood lactate 
measurements in MS  patients who fulfilled the 2005 revision of the MacDonald criteria for MS as 
well as healthy control subjects.had values of circulating lactate different from those of controls.  
We included serum samples from 1851 pPatients (1226[1] MS, 625 controlsn = 613) from three 
centers,  were recruited at the Catholic University of Rome, Italy, (n = 281), at the MS Centre 
Amsterdam, The Netherlands (n = 158) and at the S Camillo Forlanini Hospital, Rome, Italy (n = 
174). Clinical disability was assessThey were clinically assessed  using the Extended Disability 
Status Scale score (EDSS) and classified clinically according to Lublin and Reingold. Peripheral 
blood was used to determine sSerum lactate levels were quantified spectrophotometrically with the 
anlyst being blinded to all clinical information. , using the lactate oxidase-based spectrophotometric 
method. ISerum lactate in patients with MS patients serum lactate levels was about were three times 
higher (3.04 ± 1.26 mmol/l) than that of compared to serum lactate levels of 625 matched healthy 
controls (1.09 ± 0.25 mmol/l, p < 0.0001). Importantly, serum lactate levels were increase across 
When divided according to their  clinical groups with higher levels in cases with a progressive 
disease course compared to those with a characteristics, MS patients had serum lactate values 
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related to the clinical course ( relapsing-remitting, disease course secondary progressive and 
primary progressive). In addition, there was a serum lactate and the EDSS scores were linearly 
correlation between serum lactate levels and the EDSS ed (R2 = 0.419; p < 0.001). These data 
strongly suggest that M support the hypothesis that mitochondrial dysfunction is an important 
feature in MS and of particular relevance to the neurodegenerative phase of the disease.  is 
characterized by energy penalty and indicate that the determination of circulating Measurement o0f 
serum lactate in MS might be a relative inexpensive test for relevant for longitudinal monitoring of 
“virtual hypoxia” in MS. Serum lactate may also be a secondary outcome for the disease 
progression and the efficacy of  treatments trials aimed to improve mitochondrial function in 
patients with MS.drug treatments, using an inexpensive, easy to perform, low invasive analytical 
parameter.  
 
Keywords: clinical disability; energy penalty; mitochondrial dysfunction; multiple sclerosis; serum 
lactate. 
 
Abbreviations: CPK-BB = creatinphosphokinase brain specific isoform; CrP = creatine phosphate; 
EDSS = expanded disability scale; ETC = electron transport chain; 1H-MRS = proton-magnetic 
resonance spectroscopy; MS = multiple sclerosis; PP = primary progressive; RNS = reactive 
nitrogen species; ROS = reactive oxygen species; RR = relapsing remitting; SP = secondary 
progressive.  
 
4 
INTRODUCTION 
 
Multiple sclerosis (MS) is a progressive demyelinating disorder central nervous system causing 
severeaccumulation of disability to the patients up to their death. MS is believed to be an 
autoimmune pathology (Pineas and Parratt, 2012) although the reasons for the autoimmune attack 
towards myelin are not yet totally clear (Brassar, 2012). As it occurs in other chronic 
neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease), MS is characterized by 
various molecular alterations including change in ionic homeostasis (Ehling et al., 2011; 
Stadelmann, 2011), overproduction of reactive oxygen (ROS) and nitrogen species (RNS), with 
consequent oxidative/nitrosative stress and induction of apoptosis (Seven et al., 2013; Fiorini et al., 
2013; Haider et al., 2011). All these events seriously compromise many fundamental neuronal 
functions and certainly play a role in the disease progression and worsening of the patients’ clinical 
conditions. In addition, these molecular changes seem to have, as a common feature, the 
malfunctioning of mitochondria leading to formulate the “mitochondrial hypothesis” to explain 
axonal degeneration in MS (Su et al., 2009; Su et al., 2013; Cambron et al., 2012), as well as to 
formulate the concept of “virtual hypoxia” in which chronically demyelinated axons of MS patients 
are forced to operate (Trapp and Stys, 2009). 
This hypothesis is supported by many experimental and clinical data showing that MS is 
characterized by a remarkable energy penalty due to the impairment between energy production and 
consumption (Trapp and Stys, 2009; Cambron et al., 2012; Hattingen et al., 2011). This imbalance 
is determined by a decreased mitochondrial ability to supply adequate ATP concentrations for the 
various energy-dependent functions crucial for the neuronal survival. In particular, imbalance in 
creatinphosphate (CrP) homeostasis (Tur et al., 2012) and decreased activity of the brain specific 
isoform of the enzyme creatinphosphokinase (CPK-BB) detected in MS (Steen et al., 2010), should 
be responsible for the reduced export of the mitochondrially generated ATP to the cytoplasm, with 
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consequent decreased availability of cytoplasmic ATP. Contribution to a net decrease in ATP 
cellular content should also be due to an impairment in the activity of the mitochondrial electron 
transport chain (ETC). In fact, it has been demonstrated that MS patients have decreased expression 
of various subunits of complexes I, III, IV and V of the ETC in different brain regions (Pandit et al. 
2009), with consequent diminution in the electron flow through the chain and inevitable decrease in 
ATP formation by the electron-dependent oxidative phosphorylation. The overall decline in 
cytoplasmic ATP negatively influences all the ATP-dependent reactions, including the activity of 
ATP-ases involved in ionic homeostasis (Dutta et al., 2006), causing imbalance in intracellular 
calcium and membrane depolarization (Dutta et al., 2006; Andrews et al., 2005).  
In line with the hypothesis of mitochondrial malfunctioning, we have previously demonstrated that 
MS patients have increased levels of compounds deriving from ATP catabolism (hypoxanthine, 
xanthine, uric acid, uridine, creatinine) in their cerebrospinal fluid (CSF) and blood (Amorini et al., 
2009; Lazzarino et al., 2010; Tavazzi et al., 2011). These data strongly supported the concept that 
MS patients have impaired energy metabolism, with significant imbalance in the production and 
consumption of ATP (Steen et al., 2010; Tur et al., 2012) ultimately causing an overproduction of 
its catabolites in the cerebral tissue (Langemann et al., 1992). Thanks to their ability to freely cross 
the neuronal membrane, these low molecular weight compounds are initially released into the CSF 
of MS patients, subsequently reaching the blood stream, and finally leading to a significant raise in 
their concentrations in the biological fluids respect to values found in healthy controls (Amorini et 
al., 2009; Lazzarino et al., 2010; Tavazzi et al., 2011). With this current knowledge of an energy 
penalty in MS, it is reasonable to imagine that, in order to counteract the diminished ATP supply 
caused by altered mitochondrial functions, cerebral cells may tend to increase the glycolytic 
pathway to rates exceeding the already compromised capacity of mitochondria to metabolize 
pyruvate. In consequence of an increased glycolytic rate and pyruvate accumulation an increase in 
lactate production might be expected. Recently, by using proton-magnetic resonance spectroscopy 
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(1H-MRS), it has been shown that MS patients had increased lactate in their CSF, suggesting 
increased extra-mitochondrial glucose metabolism due to mitochondrial dysfunction (Regenold et 
al., 2008). A correlation between lactate concentration in CSF and the number of inflammatory 
plaques reinforced the indication of increased glycolysis in MS due to mitochondrial 
malfunctioning (Simone et al., 1996; Lutz et al., 2007). Notwithstanding, data reporting decrease in 
CSF lactate in the early stages of MS have also been published (Fonalledas Perelló et al., 2008), 
thereby rendering unclear the importance of measuring this compound. Furthermore, to increase the 
uncertainty, additional 1H-MRS studies indicated either elevated (Zaaraoui et al., 2010) or no 
change (Schocke et al., 2003) of brain lactate in MS patients. To date, no data are available 
concerning the concentration of circulating lactate in MS patients. Interestingly, a retrospective 
evaluation of the chromatographic runs of serum samples of MS patients enrolled in our previous 
studies (Amorini et al., 2009; Tavazzi et al., 2011) showed an impure peak having the retention 
time of true lactate which, in the majority of samples, was much higher than that found in controls 
(data not shown).  
In this study, we measured the concentration of serum lactate in a large cross-sectional cohort of 
MS patients, recruited in three different Centers, comparing the results with those recorded in a 
group of control, age and sex matched, healthy subjects. The hypotheses tested were firstly that an 
energy deficit in MS would lead to higher lactate levels, secondly that any rise of serum lactate in 
MS would be clinically relevant and related to clinical disability and disease course.  
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MATERIALS AND METHODS 
 
Selection and clinical evaluation of the MS patients 
Patients (n = 613) fulfilling the 2005 revision of the diagnostic panel criteria for MS (Polman et al., 
2005) were recruited at the Institute of Neurology of the “Policlinico Gemelli” of the Catholic 
University of Rome (center 1; n = 281), at the Department of Neurosciences, S Camillo Forlanini 
Hospital, Rome, Italy (center 2; n = 174) and at the Department of Neurology, VU Medical Centre, 
Amsterdam, The Netherlands (center 3; n = 158). They were clinically assessed using the Extended 
Disability Status Scale score (EDSS) (Krutzke, 1983). In coincidence with the medical examination, 
patients were asked to undergo to a blood withdrawal to be used for this research study. Only 
patients that at the moment of the blood collection were clinically stable were included in the study. 
A clinical relapse within one month before withdrawal was used as an exclusion criterion. 
Patients were classified into relapsing remitting (RR), secondary progressive (SP) or primary 
progressive (PP), according to Lublin and Reingold (Lublin and Reingold, 1996). The control group 
consisted of 625 healthy subjects, matched for age and gender, and recruited among the students of 
the Catholic University of Rome and the University of Catania, as well as among the personnel of 
these two Universities who underwent the annual health check-up. Subjects suffering from any 
acute or chronic systemic disease, which might have influenced the serum lactate levels, were not 
included in the control group. The study was approved by the local Ethic Committees and written 
informed consent was obtained from all patients according to the Declaration of Helsinki. 
 
Preparation of samples 
Peripheral venous blood samples were collected, using the standard tourniquet procedure, from the 
antecubital vein into a single VACUETTE® polypropylene tube containing serum separator and clot 
activator (Greiner-Bio One GmbH, Kremsmunster, Austria). Blood withdrawals in both controls 
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and MS patients were carried out after at least 15 minutes of complete rest. After 30 minutes at 
room temperature, samples were centrifuged at 1890 x g for 10 min to separate sera. To measure 
lactate concentration, an aliquot of all serum samples was used with no further processing. This 
protocol for blood withdrawal and serum preparation was strictly observed in the three centers 
involved and was equally used either in all controls or in all MS patients. 
 
Spectrophotometric assay of serum lactate 
The spectrophotometric determination of lactate was carried out using an Agilent 89090A 
spectrophotometer (Agilent Technologies, Santa Clara Ca, USA) and following the method 
described by Artiss et al. (Artiss et al., 2000). Briefly, the reaction mixture contained 100 mM Tris-
HCl, 1.5 mM N-ethyl-N-2-hydroxy-3-sulfopropyl-3-methylalanine, 1.7 mM 4-aminoantipirine, 5 
IU horseradish peroxidase. Fifty l of serum were added to the mixture, let to stand for 5 min and 
read at 545 nm wavelength. The reaction was started with the addition of 5 IU of lactate oxidase to 
the cuvette (finale volume = 1 ml) and it was considered ended when no change in absorbance were 
recorded for at least 3 min. To calculate lactate in serum samples, the difference in absorbance at 
545 nm wavelength (abs) of each sample was interpolated with a calibration curve obtained by 
plotting abs measured in standard solutions of lactate with increasing known concentrations  
To compare analytical results of serum lactate obtained with the afore described method, 150 
samples from the control group and 150 samples from the groups of MS patients were randomly 
selected and assayed at the “Policlinico Gemelli” Hospital of the Catholic University of Rome, 
applying the same lactate oxidase-based method and using conventional apparatus routinely used in 
the clinical biochemistry laboratory of the hospital (Cobas c 702, Roche Diagnostics). 
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Statistical analysis 
Normal data distribution of data in controls and MS patient was assessedtested using by  the 
Kolmogorov-Smirnov test. For normally districuted data, Dgroup differences between the two 
groups  were assessed by the Student’s t-test for unpaired observations. Due to the very different 
number of subjectsunbalanced study design the Kruskal-Wallis one-way ANOVA by ranks, 
followed by the Friedman test was used for comparison of , significances among controls and MS 
subgroups of MS on clinical MS subtypes (RR, SP, PP) were assessed by the and controls.Kruskal-
Wallis one-way ANOVA by ranks, followed by the Friedman test. CAnalysis of correlation and 
regression analyses fo serum lactate levels with the EDSS were, followed by ANOVA of the 
regression coefficients, was performed to estimate and test serum lactate of MS patients as a 
function of the EDSS scores. Only A two-tailed p-values of p < less than 0.05 wereas considered as 
statistically significant. 
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RESULTS 
 
The demographic and clinical data of the group of control healthy subjects and of MS patients 
enrolled in this study are summarized in Table 1. When subgrouped on the basis of the EDSS scores 
64 patients were EDSS 0, 72 EDSS 1, 26 EDSS 1.5, 76 EDSS 2, 25 EDSS 2.5, 75 EDSS 3, 37 
EDSS 3.5, 58 EDSS 4, 16 EDSS 4.5, 26 EDSS 5, 10 EDSS 5.5, 72 EDSS 6, 20 EDSS 6.5, 24 EDSS 
7, 6 EDSS 7.5 and 6 EDSS 8. The majority of patients with MS had a RR disease course (n = 430; 
70.1%), with smaller numbers of them being affected by the SP (n = 153; 25.0%) and the PP (n = 
30; 4.9%) forms. The group of RR-MS patients had significantly lower mean values of EDSS and 
disease duration compared to the corresponding values recorded in the groups of both SP-MS and 
PP-MS patients (p < 0.01). 
 
Table 1. Clinical neurolog[2]ical data of MS patients and controls. N/A = not available 
 CTRL 
(n = 625) 
MS (all) 
(n = 613) 
RR 
(n = 430) 
SP 
(n = 153) 
PP 
(n = 30) 
Age (years) 44.8 ± 11.7 
46.0 (15-73) 
45.4 ± 12.8 
46.5 (15-80) 
43.1 ±12.5 
42.0 (15-70) 
49.7 ± 11.7 
50.2 (28-72) 
51.3 ± 13.4 
53.0 (26-80) 
Gender F 420 : M 205 F 411 : M 202 F 276 : M 154 F 110 : M 43 F 21 : M 9 
Disease duration 
(years) 
N/. A.  12.9 ± 9.5 
12.0 (0-44) 
10.8 ± 9.7 
9.0 (0-38) 
18.8 ± 10.0 
18.2 (1-44) 
14.8 ± 9.8 
15.1 (0.6-35) 
EDSS N/. A.  3.3 ± 2.1 
3.0 (0-8) 
2.1 ± 1.6 
2.0 (0-8) 
5.8 ± 1.5 
6.0 (0-8) 
5.2 ± 1.5 
6.0 (3.0-8) 
 
Values are expressed as mean ± S.D. and median (range). CTRL = controls; MS (all) = total number of 
multiple sclerosis patients; PP = Primary Progressive; SP = Secondary Progressive; RR = Relapsing 
Remitting; N.A. = not assessed; EDSS = Extended Disability Status Scale score. 
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Serum lactate in controls and MS patients 
Data referring to the concentration of circulating lactate detected in serum of controls and MS 
patients are illustrated in Figure 1[3].  
 
 
Figure 1. Concentration of serum lactate determined in peripheral venous blood samples of 625 control healthy subjects 
and 613 MS patients. In Panel A, mean values with standard deviations represented by vertical bars, are reported. In 
Panel B, the individual values of each subject of both groups, with medians represented by horizontal marks (1.10 and 
2.87 in controls and MS patients, respectively), are reported. 
* significantly different from the group of sex and age matched healthy controls, p < 0.0001.  
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In our group of 625 resting healthy controls we found a mean lactate value of 1.09 ± 0.25 mmol/l 
serum (Panel A), with 615 of them having lactate ranging between 0.5 and 1.5 mmol/l serum and 10 
outliers (1.6%) with a lactate range of 1.76 ÷ 2 mmol/l serum. Independently on the clinical subtype 
and the EDSS score (Panel A), we detected a mean lactate value of 3.04 ± 1.26 mmol/l serum in 
resting MS patients, i.e. about 2.8 times higher than that of controls (p < 0.0001). As shown in the 
scatterplot of Panel B, 101 of the 613 MS patients (16.5%) had serum lactate falling within the 
range of values determined in controls (0.5 ÷ 2 mmol/l serum). The remaining 502 MS patients 
(84.5%) had values higher than the maximal concentration of circulating lactate (2.0 mmol/l) 
recorded in one control healthy subject only. In MS patients, serum lactate ranged from 0.60 mmol/l 
to 7.56 mmol/l. Analysis of the clinical and biochemical results considering MS patients as three 
separate cohorts (one for each recruiting center), are reported in Table 2. We found that the patients 
recruited at center 2 had a significantly lower EDSS scores compared to both center 1 and 3 (p < 
0.05), with center 3 having the highest mean EDSS score. Additionally, center 3 recruited the 
highest % number of PP patients respect to both centers 1 and 2. The very relevant finding is that 
the three centers had lactate values of 3.38 ± 1.83 mmol/l serum (center 1), 2.74 ± 1.39 mmol/l 
serum (center 2) and 2.94 ± 1.26 mmol/l serum (center 3), i.e. each of the three subset of MS 
patients had significantly higher lactate values than those found in healthy controls (1.09 ± 0.25 
mmol/l serum; p < 0.0001). Because of the differences in the EDSS score, lactate values recorded in 
patients recruited at center 2 were significantly lower than those measured in patients recruited in 
center 1, thus reinforcing the concept of a correlation between serum lactate and clinical status in 
MS. 
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Table 2. Clinical status and serum lactate in MS patients recruited in each per center. 
 
 MS  
(all) 
RR SP PP EDSS Serum 
lactate 
Center 1 n=281 
 
202 
(71.9%) 
72 
(25.6%) 
7 
(2.5%) 
3.82 ± 2.23 3.[4]31 ± 1.83 
Center 2 n=174 132 
(75.9%) 
37 
(21.2%) 
5 
(2.9%) 
2.18 ± 1.97 2.81 ± 1.39 
Center 3 n=158 96 
(60.8%) 
44 
(27.8%) 
18 
(11.4%9 
4.21± 1.79 2.94 ± 1.26 
 
MS  = number of [5]all Multiple  Sclerosis patients; PP = number of Primary Progressive patients (% in each 
center), SP = number of Secondary Progressive patients (% in each center); RR = number of Relapsing 
Remitting patients (% in each center); EDSS = Extended Disability Status Scale score. In the EDSS and 
serum lactate columns, values represent mean ± S.D and lactate is expressed in mmol/l serum. 
 
 
 
To confirm these analytical results and to corroborate their relevance for the clinical biochemical 
monitoring of MS patients, we reported in Table 3 values of serum lactate determined in 150, 
randomly selected, samples of controls and 150, randomly selected, samples of MS patients, in 
which lactate was assayed either with the method described above or with the conventional methods 
rout[6]inely applied in the clinical biochemistry setting. Data indicate that no significant differences 
exist in the lactate values obtained with these two methods, thereby demonstrating the analytical 
validity of the present results. 
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Table 3. Compariso[7]n of the analytical results obtained with a standard laboratory spectrophotometer and 
an apparatus in use in the clinical biochemistry setting and referring to serum lactate recorded in 150 
randomly selected samples of controls and MS patients. 
 
 Controls 
(n = 150) 
MS patients 
(n = 150) 
Serum lactate (mmol/l) 
Laboratory 
spectrophotometer 
 
1.06 ± 0.22 
 
 
3.29 ± 1.18a 
 
Serum lactate(mmol/l) 
Clinical biochemistry 
apparatus 
 
1.11 ± 0.25 
 
 
3.38 ± 1.26a 
 
 
Values are expressed as means ± S.D.  
asignificantly different from controls (p < 0.0001). 
 
 
To asses whether circulating lactate was correlated to clinical subtypes, MS patients were divided 
into RR, SP and PP and values of serum lactate in these groups were then calculated. As shown in 
Figure 2, all three subgroups of MS patients had higher values of lactate (2.72 ± 1.12, 3.86 ± 1.29 
and 3.32 ± 1.16 mmol/l serum, respectively; p < 0.0001) than those detected in controls (Panel A). 
Significant differences were recorded in the comparisons between RR and SP (p < 0.0001), RR 
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versus PP (p < 0.01), and SP versus PP (p < 0.05). Importantly, the subgroup analysis with all 
progressive patients pooled together (SP and PP) demonstrated higher serum lactate levels (3.77 ± 
1.28) compared to either RR-MS patients or  control subjects (p < 0.0001 for both comparisons), 
thus suggesting a correlation between MS subtype and serum values of this glycolytic end product 
(Figure 2, Panel B).  
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Figure 2. Concentration of serum lactate in controls and MS patients divided according to their different clinical subtype. In Panel A, 
patients were divided into three groups (RR = relapsing remitting; SP = secondary progressive; PP primary progressive) of very 
different size (RR = 430; SP = 153; PP = 30) and possibly affecting statistical significance. In Panel B, patients were divided into two 
groups (RR = 430 and SP + PP = 189). Values are reported as means, with standard deviations represented by vertical bars. 
* significantly different from the group of sex and age matched healthy controls, p < 0.001.  
** significantly different from the group of RR patients, p < 0.0001.  
 
In order to investigate the correlation with the disease progression, values of serum lactate were 
plotted as a function of the EDSS scores (Figure 3).  
 
 
Figure 3. Dispersion graphic in which 76values of serum lactate of  controls (randomly selected in the lactate values of the 625 
healthy subjects) and of each of the 613 patients were plotted as a function of the EDSS scores. To the group of the 76 controls the 
real 0 on the y axis was assigned. The value of the correlation coefficient (R2 = 0.419; p < 0.0001) indicated that the two parameters 
were linearly correlated. 
 
 
Since the number of subjects in the different EDSS subgroups did not exceed the 76 units, in order 
to avoid an excess weight of the control group in the calculation of the regression coefficients, we 
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reduced the number of controls accordingly for the further statistical comparisons (analysis of 
regression and analysis of variance on the regression coefficients). Therefore, we randomly selected 
76 values from the 625 lactate values of controls. This reduced in size control group (mean = 0.95 ± 
0.26, median = 0.88) had the same distribution (calculated using the Kolmogorov-Smirnov test) of 
the original larger control group and was used in the linear regression analysis. Lactate values in the 
control group were tabulated as the 0 values (no disease), whilst those in the MS patients were 
tabulated as the original EDSS score + 1. In Figure 3, the equation (y = 0.3657 x + 1.4289; R = 
0.6473; R2 = 0.419; p < 0.0001) describing the best fitting regression line indicate a strong positive 
correlation linking serum lactate with disease progression (increase in EDSS scores), thus 
suggesting that the worsening of the clinical conditions of MS patients is accompanied by evident 
deteriorations in their cell energy metabolism. It is however worth underlining that a consistent 
16.5% of MS patients had values of circulating lactate falling within the range of variability of 
control healthy subjects (Figure 1). These 101 “low lactate” MS patients were not found in MS 
patients scoring 3.5, 5.5, 6.5 and 7.5. on EDSS. Where present, they represented the 54.7% (EDSS 
0), 29.1% (EDSS 1), 15.4% (EDSS 1.5), 21.0% (EDSS 2), 20.0 (EDSS 2.5), 16.1% (EDSS 3), 
17.2% (EDSS 4), 10.0% (EDSS 4.5), 6.0% (EDSS 5), 11.1% (EDSS 6), 9.7% (EDSS 7) and 16.7% 
(EDSS 8) of the respective EDSS class, with an evident clustering in the EDSS 0, characterized by 
the less severe clinical symptoms. It is important to note that without considering the 10 outliers of 
the control group, having lactate ranging between 1.76 and 2 mmol/l serum and representing the 
1.6% of the 625 control values, the number of MS patients falling within the range of controls drops 
from 101 to 70 (11.5%), 
The box plot in Figure 4 shows the calculated best fitting linear regression on the medians of the 
different EDSS scores. According to the equation y = 0.3935 x + 0.83 (R = 0.9859; R2 = 0.972; p < 
0.0001) it is possible to appreciate how medians of serum lactate in MS patients linearly increased 
as a function of the increase in EDSS score. It should be observed that, since in a box plot the 
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abscissa is equally divided on the basis of the number of x values, patients with the intermediate 
EDSS scores (1.5, 2.5, 3.5, 4.5, 5.5, 6.5 and 7.5) were grouped with those of the upper EDSS class 
(1.5-2, 2.5-3, 3.5-4, 4.5-5, 5.5-6, 6.5-7 and 7.5-8), in order to have equally spaced x values. In 
addition, even in this case, the control group used in Figure 3 (n = 76) was considered as the 0 
group (no disease) and the EDSS scores + 1 were tabulated to perform the regression analysis.  
 
 
Figure 4. Box plot showing the linear correlation between the medians of the values of serum lactate recorded controls and the MS 
patients divided on EDSS scores. Values in controls refer to 76 serum lactate randomly selected in the values of the 625 healthy 
subjects. To plot this graph, patients with non integers EDSS scores were grouped with those of the nearest upper class, as indicated 
in the Figure. The value of the correlation coefficient (R2 = 0.9521; p < 0.0001) indicated a statistically significant linear correlation. 
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DISCUSSION 
 
Data reported in the present study showed, for the first time to the best of our knowledge, that MS 
patients have remarkably elevated concentration of serum lactate respect to control healthy subjects. 
Furthermore, we also found that increased levels of circulating lactate in MS patients are strictly 
associated with the EDSS scores and with the clinical MS subtype (RR, SP, PP), thereby opening 
new perspectives for an ease, low cost, low invasive monitoring of the disease progression. 
In the last decades, also thanks to the development of new imaging techniques such as 1H- and 31P-
MRS, several studies have clearly demonstrated significant metabolic changes in MS lesions and in 
normal appearing white matter suggesting that change in important metabolic functions may be 
implicated in the disease progression. In particular, decrease in NAA (Stromillo et al., 2013; Kirov 
et al., 2013; Steen et al., 2013), decrease in the total 31P peak integrals and decrease in 
phosphodiesters/total 31P (Husted et al., 1994), increase in total creatine (Kirov et al., 2013; Bagory 
et al., 2012), change in the activity of CPK-BB (Steen et al., 2010; Tur et al., 2012; Steen et al., 
2013) are all suggestive of altered mitochondrial functions and neuronal energy state. In accordance 
to these findings, we found that MS patients show significant alterations of parameters indicative of 
impaired energy metabolism, such as uric acid, hypoxanthine, xanthine, creatinine, not only in CSF 
but also in serum/plasma (Amorini et al., 2009; Lazzarino et al., 2010; Tavazzi et al., 2011). 
According to these strong indications, suggesting that MS is characterized by metabolic imbalance 
due to compromised mitochondrial functions, it is conceivable to expect that MS may cause 
increase in neuronal lactate production because of compensatory mechanisms. Data referring to 
possible changes in lactate in MS patients are controversial, since either increase (Simone et al., 
1996; Lutz et al., 2007; Regenold et al., 2008) or decrease (Fonalledas Perelló et al., 2008) in CSF 
lactate have been reported. To increase the uncertainty about changes of this compound in relation 
to MS, it should be reminded that either elevated (Zaaraoui et al., 2010) or no change (Schocke et 
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al., 2003) of brain lactate have been reported. In addition, data available in literature have mainly 
been obtained in relatively restricted cohorts of MS patients (Simone et al., 1996; Lutz et al., 2007; 
Regenold et al., 2008; Fonalledas Perelló et al., 2008). However, when lactate was found elevated 
in CSF of MS patients (Simone et al., 1996; Lutz et al., 2007; Regenold et al., 2008) no correlation 
with the disease progression on EDSS or with the clinical subtype (RR, SP, PP) has been 
demonstrated, thereby rendering doubtful the usefulness in the monitoring of this molecule in MS. 
Also, no systematic studies aimed at measuring lactate in serum/plasma of MS patients have been 
performed. Recently, it has been reported that levels of circulating lactate of patients with RR-MS 
were not different from those found in controls, even though results of this study have been 
obtained in a very small number of subjects (n = 16, for both controls and patients) even 
characterized by a low value of EDSS (Mähler et al., 2012). 
Results reported in the present study, demonstrated about 3-times higher values of circulating 
lactate in MS patients than in control healthy subjects, let to hypothesize that either hyperglycolysis 
of sclerotic plaques or activated inflammatory cells might give raise to overproduction of lactate 
which only transiently remains into the CSF and rapidly diffuses into the blood stream. This 
sequence of events might not only explain the conflicting data of literature (Simone et al., 1996; 
Lutz et al., 2007; Regenold et al., 2008; Fonalledas Perelló et al., 2008; Zaaraoui et al., 2010; 
Schocke et al., 2003), but also why the increase in CSF lactate was not found to be correlated with 
EDSS or MS clinical subtype (Simone et al., 1996; Lutz et al., 2007; Regenold et al., 2008; 
Fonalledas Perelló et al., 2008; Zaaraoui et al., 2010; Schocke et al., 2003). It might also be 
possible that lactate in MS is not constantly overproduced but that it is subjected to fluctuations; 
this would render difficult to detect significant differences respect to controls when assaying lactate 
in the nervous tissue or in CSF. To clarify this issue, it should be important to perform longitudinal 
studies. It is conceivable that most of the exceeding lactate, intermittently or constantly, flows from 
CSF to the blood, thus explaining the significant differences recorded in the concentration of serum 
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lactate, even when MS patients were divided into the RR, SP and PP clinical subtypes (Figure 2). In 
fact, we found that the SP and PP subgroups, characterized by higher mean EDSS scores (Table 1) 
due to higher neurodegenerative component leading to extensive neuroaxonal damage (Brück and 
Stadelmann, 2003), had higher circulating lactate than the RR- MS subgroup (Figure 2). 
In our cohort of 613 MS patients, when plotting the concentrations of circulating lactate as a 
function of the EDSS scores a linear correlation has been obtained (Figures 3 and 4), 
notwithstanding the presence of some outliers particularly evident in the EDSS 2.5, 6 and 8. 
Medians of 0.88 mmol/l serum for the control group and of 1.90 (EDSS 0), 2.12 (EDSS 1), 2.58 
(EDSS 1.5-2), 2.78 (EDSS 2.5-3), 3.04 (EDSS 3.5-4), 3.60 (EDSS 4.5-5), 3.75 (EDSS 5.5-6), 4.61 
(EDSS 6.5-7) and 4.71 (EDSS 7.5-8) for the MS patients divided on EDSS scores (Figure 4), 
strongly support the hypothesis of a metabolic impairment associated with the progression of the 
disease. However, it can be postulated that neither inflammation nor hyperglycolysis at the sclerotic 
plaques are sufficient to cause such a remarkable increase (up to 5 times the median value of 
controls) in the values of circulating lactate. According to previous data, MS patients showed an 
abnormal intramuscular component of fatigue (Sharma et al., 1995) and, those with mild disability, 
evidenced an increased cost of walking (Taylor et al., 2006; Franceschini et al., 2010). Both 
findings suggest the potential muscular involvement in MS, possibly caused by a metabolic 
imbalance of myocytes, and let to assume that part of the elevated circulating lactate detected in our 
cohort of MS patients is of muscular origin. It is certainly important to observe that not all MS 
patients had serum lactate higher than that found in controls. A consistent 16.5% of them had values 
of circulating lactate falling within the range of variability of control healthy subjects (Figure 1). 
It is reasonable to suppose that the increase of lactate, may trigger (or may be the result of) a vicious 
circle in which the compensatory product of mitochondrial malfunctioning (lactate) may contribute 
to worsen mitochondrial activity itself. In fact, the intracellular acidification caused by increased 
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lactate production may cause dramatic adverse effects on various and cell functions, including 
mitochondrial functions (Robergs et al., 2004). 
One important additional observation that can be drawn from the results reported in this study is 
certainly related to the potential use of serum lactate determination to follow the disease progression 
in MS patients, as well as to monitor the eventual benefits of a pharmacological treatment. In spite 
of the very many efforts devoted to find new reliable biomarkers correlated with MS progression 
(Dujmovic 2011; Ziemann et al., 2011; Pravica et al., 2012; Singh et al., 2012; Tourdias and 
Dousset, 2013), to date clinicians are still waiting to know what should be assayed in order to have 
objective parameters, easily measurable, with which predicting the evolution of the disease or 
following the efficacy of drug administration. It may also be affirmed that clinicians are also 
waiting to know where this potential biomarker should be assayed: (post mortem) brain tissue, CSF, 
blood, extracellular fluid. At present, most of the proposed biomarkers are expensive in terms of 
cost of analysis (MRS, MRI, immunogenic profile, CD lymphocyte profile, antibodies detection, 
etc.), of invasiveness (lumbar puncture), of still uncertain reliability.  
Detection of serum lactate is characterized by a very low cost, limited invasiveness, high 
automation, high reproducibility: the present results, indicating high correlation with the MS 
progression and MS clinical subtypes, suggest that lactate has all the characteristics of one of the 
best candidate to become one of the biomarkers of choice to follow MS progression and drug 
efficacy. It may be easily hypothesized that a frequent serum lactate determination would be of 
great help for physicians in knowing how an MS patient responds to a given therapy and how the 
disease is progressing. Also, improvement in the quality of results obtainable by the use of the so 
called “lactometer” for the self-made lactate measurement might allow an even more frequent 
measurement of this new potential biomarker. 
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